All patients should be tested for DPD deficiency before starting 5-fluorouracil (intravenous), capecitabine and tegafur. All relevant protocols will be updated with this requirement at their next review.
Full guidance below:
http://www.kmcc.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=467537
https://www.gov.uk/drug-safety-update/5-fluorouracil-intravenous-capecitabine-tegafur-dpd-testing-recommended-before-initiation-to-identify-patients-at-increased-risk-of-severe-and-fatal-toxicity
Access to Free of Charge Drugs Outside of Clinical Trials (via Access Schemes or Early Access to Medicine Schemes) v1
Overview
SOP-001 Standard Operating Procedure for the Maintenance of the Kent and Medway Cancer Collaborative (KMCC) Regimens Spreadsheets for Oncology and Haematology v1
Protocols for Oral Anti-Cancer Treatments Dispensed in the Community
Supportive Care Guidelines & Supplementary Information Guidelines
Procarbazine
Proformas and Protocols
Anal
Brain & CNS
Breast
Colorectal
Head and Neck
Renal Cell Carcinoma
Skin
Supportive Care
Upper GI
Urology